gptkbp:instanceOf
|
amphetamine
Hallucinogen
|
gptkbp:category
|
recreational drug
psychedelic phenethylamine
substituted phenethylamine
|
gptkbp:chemicalFormula
|
C10H15NO2
|
gptkbp:discoveredBy
|
gptkb:Alexander_Shulgin
|
gptkbp:duration_of_effects
|
4 to 6 hours
|
gptkbp:effect
|
psychedelic
hallucinogenic
entactogenic
|
gptkbp:firstSynthesized
|
1970
|
gptkbp:hasSMILES
|
CC1=CC(OC)=C(CCN)C=C1OC
|
https://www.w3.org/2000/01/rdf-schema#label
|
2C-D
|
gptkbp:IUPACName
|
2,5-dimethoxy-4-methylphenethylamine
|
gptkbp:legal_status_in_Canada
|
Schedule III controlled substance
|
gptkbp:legal_status_in_Germany
|
Anlage I controlled substance
|
gptkbp:legal_status_in_United_Kingdom
|
Class A drug
|
gptkbp:legal_status_in_United_States
|
Schedule I controlled substance
|
gptkbp:mentions
|
gptkb:PiHKAL
|
gptkbp:molecularWeight
|
181.23 g/mol
|
gptkbp:otherName
|
2,5-dimethoxy-4-methylphenethylamine
2C-M
|
gptkbp:PubChem_CID
|
19132
|
gptkbp:relatedTo
|
gptkb:2C-E
gptkb:2C-B
gptkb:2C-I
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
gptkbp:UNII
|
6Z6X5W1E3D
|
gptkbp:bfsParent
|
gptkb:NBOMe_series
gptkb:2C_family
|
gptkbp:bfsLayer
|
7
|